Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SelvitaFRA:787 +1.48%75 EV-to-EBITDA is 11.24 as of Aug. 12, 2026, which is 47% below its 10-year median of 21.35. GuruFocus rates FRA:787 with a GF Score™ of 75/100 and a GF Value™ of €13.38. The stock has 4 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Selvita ranks better than 63.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Selvita's enterprise value is €155.90 Mil.
Selvita's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €13.87 Mil. Therefore, Selvita's EV-to-EBITDA for today is 11.24.
The historical rank and industry rank for Selvita's EV-to-EBITDA or its related term are showing as below:
FRA:787'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.6 Med: 21.35 Max: 109.51
Current: 11.34
During the past 11 years, the highest EV-to-EBITDA of Selvita was 109.51. The lowest was 9.60. And the median was 21.35.
FRA:787's EV-to-EBITDA is ranked better than 63.56% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.925
vs FRA:787: 11.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Selvita's share price for today is €6.19.
Selvita's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.047.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Selvita's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:787 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Selvita's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Selvita EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Selvita's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Selvita's EV-to-EBITDA falls into.
Selvita's current Enterprise Value is €155.90 Mil.
Selvita's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Selvita (FRA:787) has a EV-to-EBITDA of 11.24 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Selvita. This is 47% below median its historical median of 21.35. Over the past decade, Selvita's EV-to-EBITDA has ranged from 9.60 to 109.51. According to the industry distribution chart, Selvita ranks #43 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 36.4%.
Is Selvita's EV-to-EBITDA too high?
Selvita's current EV-to-EBITDA of 11.24 is 47% below median its 10-year median of 21.35. Over the past 10 years, this metric has ranged from a low of 9.60 to a high of 109.51. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.93. Selvita's value of 11.24 is 29.4% below this industry median. Based on the distribution chart, Selvita ranks #43 out of 118 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Selvita has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Selvita's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Selvita ranks #43 out of 118 companies for EV-to-EBITDA. This puts Selvita in the upper half of its industry. The industry median EV-to-EBITDA is 15.93. Selvita's value of 11.24 is 29.4% below this benchmark. Historically, Selvita's own EV-to-EBITDA has ranged from 9.60 to 109.51 over the past decade. While the company's 10-year median is 21.35 vs. the industry median of 15.93, Selvita has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.93, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Selvita's current EV-to-EBITDA of 11.24 is 29.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Selvita. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Selvita's current EV-to-EBITDA is 11.24, which is 47% below median its own 10-year median of 21.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Selvita stock overvalued right now?
Selvita (FRA:787) has a current EV-to-EBITDA of 11.24. The stock's GF Value™ is €13.38, compared to a current price of €6.19 — trading 53.7% below its estimated fair value. The current EV-to-EBITDA is 11.24, which is 47% below median its 10-year median of 21.35 and 29.4% below the Medical Diagnostics & Research industry median of 15.93. Selvita's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Selvita (FRA:787), the current EV-to-EBITDA is 11.24 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Selvita (FRA:787) Overvalued in 2026?
Based on GuruFocus' analysis, Selvita stock appears to be undervalued.
The current stock price of €6.19 is trading 53.7% below its estimated GF Value™ of €13.38.
Key valuation signals for FRA:787:
EV-to-EBITDA: 11.24 (47% below median its 10-year median of 21.35)
GF Value™: €13.38 vs. price of €6.19 (53.7% below fair value)
Industry Position: 29.4% below the Medical Diagnostics & Research median (#43 of 118)
No single metric tells the full story. See the FRA:787 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Selvita SA is a Poland based parent company of Selvita Group is one of the largest preclinical contract research organizations in Europe. It also develops bioinformatics solutions supporting innovative projects at preclinical stages. It also provides services provided to external contractors are in the field of chemistry, analytics, regulatory, biochemistry and cell biology and also the integrated research and development projects.
75GF Score
Get the complete analysis for FRA:787
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:787 has been successfully added to your 
